GlaxoSmithKline update: influenza A (H1N1)
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) is committed to supporting governments and health authorities around the world to respond to the emergence of the new influenza A (H1N1) strain. The company has developed a number of potential interventions which it believes may be of value in efforts to reduce the impact and spread of this new influenza virus.
Outcome of new Mirapexin®/Sifrol® (pramipexole) study
- Details
- Category: Boehringer Ingelheim
Results from an international, placebo-controlled trial,(1) presented for the first time at the American Academy of Neurology (AAN) Annual Meeting in Seattle, U.S.A. demonstrate that Mirapexin® / Sifrol® (pramipexole) also improves depressive symptoms, a common, disabling non-motor symptom of Parkinson's disease (PD), in addition to its established efficacy in treating the motor symptoms of PD.
Bayer and Ardea Biosciences Enter Global Agreement Focused on the Development of MEK Inhibitors
- Details
- Category: Bayer
Bayer HealthCare AG, Germany has entered into a global agreement with Ardea Biosciences, Inc., San Diego California, USA (Nasdaq: RDEA) focused on the development of small molecule mitogen-activated ERK kinase (MEK) inhibitors for the treatment of solid tumors. These kinases are believed to play an important role in cancer cell proliferation, apoptosis and metastasis, as well as inflammation.
Pfizer Reports First-Quarter 2009 Results
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) has reported financial results for first-quarter 2009. Revenues were $10.9 billion, a decrease of 8% compared with the year-ago quarter. Foreign exchange unfavorably impacted revenues by approximately $640 million or 5%. For first-quarter 2009, U.S. revenues were $5.0 billion, a decrease of 10% compared with the year-ago quarter.
Q1/2009: Merck Revenues Remain Stable at € 1.9 Billion
- Details
- Category: Merck Group
All in all, the Merck Group performed solidly during the first quarter of 2009. However, Merck is not an island. The recession is affecting the company's results, mainly in the Chemicals business sector. In addition, this year's first quarter is compared to a very strong first quarter in 2008.
Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) announced that the U.S. District Court for the Southern District of Indiana has issued a preliminary injunction to prevent the launch of a generic version of Lilly's medicine Evista(R) (raloxifene HCl tablets) by Teva Pharmaceuticals until the Court renders its final ruling.
Pfizer And University College London Announce Collaboration To Advance Development Of Stem Cell-Base
- Details
- Category: Pfizer
Pfizer Regenerative Medicine today announced that it has entered into a collaboration and license agreement with University College London focused on gaining better understanding into how to develop stem cell-based therapies for certain ophthalmic conditions. The Pfizer/UCL collaboration brings together the pioneering work of university researchers in the field of cell-based therapies and Pfizer's expertise in the design and delivery of therapeutics.
More Pharma News ...
- Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
- Pfizer and Medicines for Malaria Venture Advancing International Research Efforts
- Roche strongly outperforms market in first quarter
- OTC weight loss aid is available in pharmacies across Europe
- Sanofi-aventis to acquire BiPar Sciences, a US biopharmaceutical company
- Abbott Reports 16 Percent Earnings Growth in First Quarter
- Roche Diabetes Care supports "Changing Diabetes in Children"